AEM vs AXTA

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

AXTA's deterministic scorecard shows a Piotroski F-Score of 4/9, indicating stable but not strong financial health, and the absence of an Altman Z-Score prevents a full distress risk assessment. The stock trades below the growth-based intrinsic value of $48.10 but above the conservative Graham Number of $22.25, suggesting mixed valuation signals. Despite solid profitability metrics like a 21.33% ROE and consistent earnings beats, revenue is contracting YoY by 2.40%, and insider activity is bearish with recent selling. Analysts recommend a 'buy' with a $36.71 target, implying moderate upside from current levels around $33.62.